113 related articles for article (PubMed ID: 3946388)
21. Local production of anti-vibrio cholerae mucosal antibody in reproductive tract tissues after cholera.
Ryan ET; Bridges EA; Crean TI; Gausia K; Hamadani JD; Aziz A; Hawkes S; Begum M; Bogaerts J; Faruque SM; Salam MA; Fuchs GJ; Calderwood SB
J Infect Dis; 2001 Sep; 184(5):643-7. PubMed ID: 11494170
[TBL] [Abstract][Full Text] [Related]
22. Use of cholera toxoid in an enzyme-linked immunosorbent assay for antitoxin.
Cruce DD; Wachsmuth IK; Feeley JC
Diagn Immunol; 1983; 1(2):87-9. PubMed ID: 6680095
[TBL] [Abstract][Full Text] [Related]
23. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
[TBL] [Abstract][Full Text] [Related]
24. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.
Svennerholm AM; Jertborn M; Gothefors L; Karim AM; Sack DA; Holmgren J
J Infect Dis; 1984 Jun; 149(6):884-93. PubMed ID: 6736680
[TBL] [Abstract][Full Text] [Related]
25. Escherichia coli heat-labile enterotoxin: comparison of antitoxin assays and serum antitoxin levels.
Wachsmuth IK; Wells JG; Ryder RW
Infect Immun; 1977 Nov; 18(2):348-51. PubMed ID: 336543
[TBL] [Abstract][Full Text] [Related]
26. Seroepidemiology of cholera in Gulf coastal Texas.
Hunt MD; Woodward WE; Keswick BH; Dupont HL
Appl Environ Microbiol; 1988 Jul; 54(7):1673-7. PubMed ID: 3415232
[TBL] [Abstract][Full Text] [Related]
27. Protective antitoxic cholera immunity in mice: influence of route and number of immunizations and mode of action of protective antibodies.
Lange S; Holmgren J
Acta Pathol Microbiol Scand C; 1978 Aug; 86C(4):145-52. PubMed ID: 696335
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae.
Chen WH; Garza J; Choquette M; Hawkins J; Hoeper A; Bernstein DI; Cohen MB
Clin Vaccine Immunol; 2015 Jan; 22(1):129-35. PubMed ID: 25410205
[TBL] [Abstract][Full Text] [Related]
29. [Value of vibriocidal antibody research in endemic areas of Vibrio cholerae 0:1].
Bendib A; Bougoudogo F; Messast M; Rezkallah D; Hamchi L; Bellouche Y; Aidoud NS; Keddouri A; Fournier JM; Dodin A
Bull Soc Pathol Exot; 1994; 87(1):33-7. PubMed ID: 8003902
[TBL] [Abstract][Full Text] [Related]
30. Duration of infection-derived immunity to cholera.
Levine MM; Black RE; Clements ML; Cisneros L; Nalin DR; Young CR
J Infect Dis; 1981 Jun; 143(6):818-20. PubMed ID: 7252264
[TBL] [Abstract][Full Text] [Related]
31. Serological studies in cholera infection in Calcutta (1966-67).
Deb BC; Ganguly R; Sinho R; Ghosh AK; Succar BK; Abou-Gareeb AH; Ozawa A; Shrivastava DL; Burrows W
Indian J Med Res; 1973 Feb; 61(2):169-78. PubMed ID: 4758991
[No Abstract] [Full Text] [Related]
32. Antibodies against Vibrio cholerae lipopolysaccharide, cell-bound haemagglutinin and toxin in the intestinal fluid during convalescence.
Chongsa-Nguan M; Chaicumpa W; Kalambaheti T; Surachedchai Y; Thanungkul B
Southeast Asian J Trop Med Public Health; 1987 Mar; 18(1):33-8. PubMed ID: 3660066
[TBL] [Abstract][Full Text] [Related]
33. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera.
Clemens JD; van Loon F; Sack DA; Chakraborty J; Rao MR; Ahmed F; Harris JR; Khan MR; Yunus M; Huda S
J Infect Dis; 1991 Jun; 163(6):1235-42. PubMed ID: 2037789
[TBL] [Abstract][Full Text] [Related]
34. Protection against experimental cholera by oral or parenteral immunization.
Peterson JW
Infect Immun; 1979 Nov; 26(2):594-8. PubMed ID: 546789
[TBL] [Abstract][Full Text] [Related]
35. Microtiter enzyme-linked immunosorbent assay for immunoglobulin G cholera antitoxin in humans: method and correlation with rabbit skin vascular permeability factor technique.
Young CR; Levine MM; Craig JP; Robins-Browne R
Infect Immun; 1980 Feb; 27(2):492-6. PubMed ID: 7189746
[TBL] [Abstract][Full Text] [Related]
36. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
[TBL] [Abstract][Full Text] [Related]
37. Current status of cholera and rise of novel mucosal vaccine.
Yamamoto T
Jpn J Infect Dis; 2000 Oct; 53(5):181-8. PubMed ID: 11135702
[TBL] [Abstract][Full Text] [Related]
38. Immunochromatographic detection of the heat-labile enterotoxin of enterotoxigenic Escherichia coli with cross-detection of cholera toxin.
Arimitsu H; Sasaki K; Tsuji T
J Microbiol Methods; 2017 Jan; 132():148-152. PubMed ID: 27940044
[TBL] [Abstract][Full Text] [Related]
39. Induction of a mucosal antitoxin response and its role in immunity to experimental canine cholera.
Pierce NF; Cray WC; Sircar BK
Infect Immun; 1978 Jul; 21(1):185-93. PubMed ID: 711314
[TBL] [Abstract][Full Text] [Related]
40. Immunobiological relationships between Vibrio fluvialis and Vibrio cholerae enterotoxins.
Ahsan CR; Sanyal SC; Zaman A; Neogy PK; Huq MI
Immunol Cell Biol; 1988 Jan; 66 ( Pt 3)():251-2. PubMed ID: 3155161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
